{"id":"NCT02392559","sponsor":"Amgen","briefTitle":"Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders","officialTitle":"Double-blind, Randomized, Multicenter, Placebo-Controlled Study to Characterize the Efficacy, Safety, and Tolerability of 24 Weeks of Evolocumab for LDL-C Reduction in Pediatric Subjects 10 to 17 Years of Age With HeFH","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-03-24","primaryCompletion":"2019-11-25","completion":"2019-11-25","firstPosted":"2015-03-19","resultsPosted":"2020-07-15","lastUpdate":"2022-11-08"},"enrollment":158,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Heterozygous Familial Hypercholesterolemia"],"interventions":[{"type":"DRUG","name":"Evolocumab","otherNames":["AMG 145; EvoMab"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"EvoMab 420 mg QM","type":"EXPERIMENTAL"}],"summary":"A study to assess safety and efficacy of evolocumab (AMG-145) in paediatric subjects aged 10-17 years diagnosed with heterozygous familial hypercholesterolemia.","primaryOutcome":{"measure":"Percent Change From Baseline to Week 24 in LDL-C","timeFrame":"Baseline, Week 24","effectByArm":[{"arm":"Placebo","deltaMin":-6.23,"sd":3.08},{"arm":"EvoMab 420 mg QM","deltaMin":-44.53,"sd":2.17}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"},{"comp":"OG000 vs OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"10 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":6},"locations":{"siteCount":66,"countries":["United States","Australia","Austria","Belgium","Brazil","Canada","Colombia","Czechia","Finland","Greece","Hungary","Italy","Malaysia","Netherlands","New Zealand","Norway","Poland","Portugal","Russia","Slovenia","South Africa","Spain","Switzerland","Taiwan","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["32865373","30318065","36210291","33078867"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":53},"commonTop":["Nasopharyngitis","Headache","Gastroenteritis","Influenza","Upper respiratory tract infection"]}}